2019

On behalf of the programme chairs, we are delighted to invite you to GIO-Med 2019, the Gilead Immuno-Oncology Medical Education Programme focussing on an introduction to CAR-T therapy in the UK. A specially invited international faculty of CAR-T experts will present live at each event and also via webcast from the central meeting in Manchester. See the meeting programmes for full details.

Topics will include:

  • An introduction and scientific overview of CAR-T therapy.
  • A holistic view of CAR-T in the UK.
  • An overview of the current CAR-T patient selection guidelines.
  • Panel debate and discussion: Will CAR-T replace stem cell therapy?
  • An overview of primary mediastinal large B-cell lymphoma & national guidelines
  • …and a reality check! – What about patients who can’t take CAR-T therapy?

We look forward to welcoming you to these meetings which take place simultaneously on 12th September 2019 (with a second day in Manchester only featuring expert-led workshop sessions)

Manchester
Thursday 12th - Friday 13th September 2019
09:30 – 15:30
London
Thursday 12th September 2019
09:30 – 15:30
Cardiff
Thursday 12th September 2019
09:30 – 15:30

Continuing Professional Development (CPD) accreditation for the UK meetings has been applied to the Royal College of Physicians (RCP) and more information will be available shortly. Please note, CPD credits obtained through RCP will be accepted by other medical colleges such as the Royal College of Pathologists and the Royal College of Nursing.

This is a medical education meeting organised and funded by Gilead Sciences Ltd., a science-based pharmaceutical company. This meeting is a medical education programme designed for healthcare professionals based in the UK and the Republic of Ireland only.

ONC/UK/19-03/PMAR/1117f
Date of preparation: May 2019

This activity is intended for medical Haematology/Oncology healthcare professionals, scientists and academics involved in the management of, and research into CAR T-cell therapy in patients with high-grade lymphoid malignancies, specifically relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), as well as those with interest in the wider treatment landscape of haematological malignancies. Data on licensed CAR-T products will be presented.